PEPIDH1M vaccine + vorasidenib

PEPIDH1M vaccine + vorasidenib is an investigational combination therapy being studied for the treatment of IDH-mutant gliomas. Vorasidenib is a first-in-class, orally administered, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes. It works by inhibiting both mutant and wild-type variants of IDH1 and IDH2, reducing the production of the oncometabolite D-2-hydroxyglutarate (2-HG), which promotes tumor growth in glioma cells. The PEPIDH1M vaccine is a tumor-specific peptide vaccine designed to stimulate an immune response against tumors harboring specific mutations such as those in IDH1. This combination aims to leverage both targeted inhibition of oncogenic metabolism (via vorasidenib) and immunotherapy (via PEPIDH1M vaccine) to improve outcomes for patients with diffuse gliomas carrying susceptible IDH mutations[1][3].

Brand names

Voranigo